Chang Hyeun Kim

Prof. Chang Hyeun Kim

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in World Neurosurgery
Verified
Journal Article
Closed access
TKTackeun Kim
Tackeun Kim
CKChang Hyeun Kim
Chang Hyeun Kim
SKSi-Hyuck Kang
Si-Hyuck Kang
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon

1 November 2021 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
CKChang Hyeun Kim
Chang Hyeun Kim
CLChi Hyung Lee
Chi Hyung Lee
YKYoung Ha Kim
Young Ha Kim
SSSoonki Sung
Soonki Sung
DSDong Wuk Son
Dong Wuk Son
GSGeun Sung Song
Geun Sung Song
Objective : Vertebral artery dissecting aneurysm (VADA) is a very rare subtype of intracranial aneurysms; when ruptured, it is associated with significantly high rates of morbidity and mortality. Despite several discussions and debates, the optimal treatment for VADA has not yet been established. In the last 10 years, flow diverter devices (FDD) have emerged as a challenging and new treatment method, and various clinical and radiological results have been reported about their safety and effectiveness. The aim of our study was to evaluate the clinical and radiological results with the use of FDD in the treatment of unruptured VADA.Methods : We retrospectively evaluated the data of all patients with unruptured VADA treated with FDD between January 2018 and February 2021 at our hybrid operating room. Nine patients with unruptured VADA, deemed hemodynamically unstable, were treated with FDD. Among other parameters, the technical feasibility of the procedure, procedure-related complications, angiographic results, and clinical outcomes were evaluated.Results : Successful FDD deployment was achieved in all cases, and the immediate follow-up angiography showed intra-aneurysmal contrast stasis with parent artery preservation. A temporary episode of facial numbness and palsy was noted in one patient; however, the symptoms had completely disappeared when followed up at the outpatient clinic 2 weeks after the procedure. The 3–6 months follow-up angiography (n=9) demonstrated complete/near-complete obliteration of the aneurysm in seven patients, and partial obliteration and segmental occlusion in one patient each. In the patient who achieved only partial obliteration, there was a sac 13 mm in size, and there was no change in the 1-year follow-up angiography. In the patient with segmental occlusion, the cause could not be determined. The clinical outcome was modified Rankin Scale 0 in all patients.Conclusion : Our preliminary study using FDD to treat hemodynamically unstable unruptured VADA showed that FDD is safe and effective. Our study has limitations in that the number of cases is small, and it is not a prospective study. However, we believe that the study contributes to evidence regarding the safety and effectiveness of FDD in the treatment of unruptured VADA.

1 January 2017 in Korean Journal of Neurotrauma
Verified
Journal Article
Open access
PDF file
CKChang Hyeun Kim
Chang Hyeun Kim
GSGeun Sung Song
Geun Sung Song
YKYoung Ha Kim
Young Ha Kim
YKYoung Soo Kim
Young Soo Kim
SSSoon Ki Sung
Soon Ki Sung
SLSang Weon Lee
Sang Weon Lee
Kim CH, et al. Korean J Neurotrauma. 2017 Oct;13(2):144-148. https://doi.org/10.13004/kjnt.2017.13.2.144

16 June 2022 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon
YKYoung Deok Kim
Young Deok Kim
BKBum-Tae Kim
Bum-Tae Kim
JOJAE SANG OH
JAE SANG OH
KSKorean NeuroEndovascular Society
Korean NeuroEndovascular Society
Objective : Stent-assisted coil embolization (SAC) has been increasingly used to treat various types of intracranial aneurysms. Delayed thromboembolic complications are major concerns regarding this procedure, so dual antiplatelet therapy with aspirin and clopidogrel is needed. However, clinicians vary the duration of dual antiplatelet therapy after SAC, and no randomized study has been performed. This study aims to compare the safety and efficacy of long-term (12 months) dual antiplatelet therapy and shortterm dual antiplatelet therapy (6 months) after SAC for patients with unruptured intracranial aneurysms (UIAs).Methods : This is a prospective, randomized and multicenter trial to investigate the optimal duration of dual antiplatelet therapy after SAC in patients with UIAs. Subjects will receive dual antiplatelet therapy for 6 months (short-term group) or 12 months (longterm group) after SAC. The primary endpoint is the assessment of thromboembolic complications between 1 and 18 months after SAC. We will enroll 528 subjects (264 subjects in each group) and perform 1 : 1 randomization. This study will involve 14 topperforming, high-volume Korean institutions specializing in coil embolization.Results : The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up.Conclusion : This article describes that the aim of this prospective randomized multicenter trial is to compare the effect of short-term (6 months) and long-term (12 months) dual antiplatelet therapy on UIAs in patients undergoing SAC, and to find the optimal duration.

1 January 2020 in Korean Journal of Neurotrauma
Verified
Journal Article
Open access
PDF file
YKYoung Ha Kim
Young Ha Kim
SLSang Weon Lee
Sang Weon Lee
DKDong Hyun Kim
Dong Hyun Kim
CLChi Hyung Lee
Chi Hyung Lee
CKChang Hyeun Kim
Chang Hyeun Kim
GSGeun Sung Song
Geun Sung Song
Kim YH, et al. Korean J Neurotrauma. 2020 Oct;16(2):181-189. https://doi.org/10.13004/kjnt.2020.16.e46

1 November 2023 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
CKChang Hyeun Kim
Chang Hyeun Kim
NHNoah Hong
Noah Hong
JRJong-Kook Rhim
Jong-Kook Rhim
JMJong Hyeon Mun
Jong Hyeon Mun
JLJeongwook Lim
Jeongwook Lim
YCYoung Dae Cho
Young Dae Cho
OBJECTIVE: Antiplatelet medication is required after stent-assisted coil embolization (SACE) to avoid thromboembolic complications. Currently, there is no consensus on how long the antiplatelet agent should be maintained. The authors investigated clinical outcomes in patients who discontinued their antiplatelet agent 12–24 months after SACE. METHODS: Data were retrieved from a prospective database for 373 consecutive patients with SACE at 6 institutions who discontinued antiplatelet therapy 12–24 months after SACE. Thromboembolic complications associated with discontinuation were defined as neurological or radiographic ischemia that occurred within 6 months after discontinuation of the antiplatelet agent; the lesion had to be correlated with the territory of the stented artery. RESULTS: The mean time until discontinuation of the antiplatelet medication was 15.8 ± 4.7 months after SACE (12–18 months, n = 271; 19–24 months, n = 102). The most common location of treated aneurysms was the internal carotid artery (n = 223, 59.8%). A laser-cut open-cell stent was most commonly applied (n = 236/388, 60.8%), followed by laser-cut closed-cell stents (n = 119, 30.7%) and braided closed-cell (n = 33, 8.5%); double stenting was applied in 15 aneurysms. There were no patients who experienced cerebral ischemia related to discontinuation of antiplatelet medications, except for 1 patient at high risk of ischemia (0.27%, 95% CI 0.01%–1.48%). CONCLUSIONS: These results suggest that it may be safe to discontinue antiplatelet medication after SACE in patients at low risk for ischemia, and that it appears safe to discontinue the agent at approximately 15 months after the procedure. Large cohort-based prospective studies or randomized clinical trials are warranted to confirm these results.